Tissue collected earlier in the pathogenic process may demonstrate increased binding of Smad3 to the ITGB6 promoter, however obtaining human lung tissue from IPF patients with newly diagnosed IPF is problematic. This evidence concerns the gene SMAD3 and idiopathic pulmonary fibrosis.